Documents
Application Sponsors
Marketing Status
Application Products
001 | TABLET;ORAL | 250MG;125MG | 1 | ADVIL DUAL ACTION WITH ACETAMINOPHEN | ACETAMINOPHEN; IBUPROFEN |
FDA Submissions
TYPE 4; Type 4 - New Combination | ORIG | 1 | AP | 2020-02-28 | STANDARD |
LABELING; Labeling | SUPPL | 3 | AP | 2022-01-10 | STANDARD |
LABELING; Labeling | SUPPL | 4 | AP | 2022-01-25 | STANDARD |
Submissions Property Types
ORIG | 1 | Null | 7 |
SUPPL | 3 | Null | 7 |
SUPPL | 4 | Null | 7 |
CDER Filings
GLAXOSMITHKLINE
cder:Array
(
[0] => Array
(
[ApplNo] => 211733
[companyName] => GLAXOSMITHKLINE
[docInserts] => ["",""]
[products] => [{"drugName":"ADVIL DUAL ACTION WITH ACETAMINOPHEN","activeIngredients":"ACETAMINOPHEN; IBUPROFEN","strength":"250MG;125MG","dosageForm":"TABLET;ORAL","marketingStatus":"Over-the-counter","te":"None","rld":"Yes","rs":"Yes"}]
[labels] => [{"actionDate":"02\/28\/2020","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/211733Orig1s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"02\/28\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 4 - New Combination","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/211733Orig1s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/211733Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2020\\\/211733Orig1s000TOC.cfm\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2020-02-28
)
)